Although pharmacological treatments of β-blockers and angiotensin-converting enzyme (ACE) inhibitors [46,47] are beneficial for patients with MI, these existing approaches require exploring new treatment methods aimed at regenerating the infarcted myocardium, as well as their implementation in clinical practice [48]. This evidence concerns the gene ACE and myocardial infarction.